Estrogen in Patients with Prostatic Cancer

  title={Estrogen in Patients with Prostatic Cancer},
  author={Peter Henriksson},
  journal={Drug Safety},
SummaryEstrogen therapy of patients with prostatic carcinoma appears to be at least as effective in antitumour activity as surgical castration; the recent therapeutic alternative of gonadorelin (gonadotrophin-releasing hormone) analogues has not to date been shown to improve patient outcome.Oral estrogen therapy in these patients increases the incidence of arterial ischaemic events, thromboembolic events and congestive heart failure. A plausible mechanism behind the enhanced cardiovascular… 
4 Citations

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.

Small noncomparative trials reveal that leuprorelin also causes regression of benign hyperplastic prostate tissue with corresponding relief of obstructive, but not irritative, symptoms although continuous treatment is necessary to maintain remission.

Increased Mean Platelet Volume after Oestrogen Replacement Therapy

HRT appears to increase mean platelets volume which may indicate an increase in platelet reactivity, and there was no correlation between the changes in mean platelet volume and membrane fatty acid changes in platelets after such therapy.

Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients

It was found that both EE/EP and EM treatment induced significant decreases of orosomucoid, haptoglobin, antithrombin III and C1-inhibitor, while the same treatment increased the plasma concentration of alpha-1-antitrypsin.



Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma.

The results of this study show that only high-dose estrogen therapy is accompanied by a selective decrease in AT-III activity, which may be an important etiological factor in the increased risk of thromboembolism in patients treated by this regime.

Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen.

If patients with prostatic cancer are examined by means of exercise stress tests and blood tests for luteinizing hormone, cholesterol, and follicle-stimulating hormone prior to treatment, the discriminant function enables the authors to identify an extremely high-risk group for cardiovascular complications if estrogen therapy is commenced.

Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer.

It is recommended that a patient with ST-segment depression during an exercise test and/or a high luteinising hormone concentration should not be treated with oestrogen, and 2 strong discriminating variables for cardiovascular complications if oestrogens therapy is instituted in patients with prostatic cancer but without overt clinical cardiovascular disease are identified.

Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate

Patients treated with a 5.0‐mg daily dose of diethylstilbestrol (DES) had an increased incidence of fatal and non‐fatal cardiovascular disease when compared to placebo in all stages of prostatic

Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma.

Parenteral administration of oestrogen caused a less marked change in the coagulation system than oral administration and should be the treatment of choice for prostatic carcinoma.

Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.

Cardiovascular complications categorized as impaired arterial circulation including ischemic heart disease, venous thromboembolism, cardiac incompensation and cerebral depression were found to be equally frequent following the two different forms of treatment.

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

The 1.0-mg dose has been as effective as the 5.0‐mg dose in controlling the prostate cancer, but it does not seem to be associated with the excess risk of cardiovascular death.

Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.

The most serious complications were cardiovascular, including ischemic heart disease, cardiac decompensation, cerebral ischemia and venous thromboembolism, which occurred in 24 patients from group A and 9 from group B as compared to only one patient in group C.